As the obesity epidemic rages across the globe, new weight loss drugs have become so popular that some manufacturers are unable to meet patient demand. Dr. David Katz, founder and CEO of Diet ID, joins Double Take to discuss investment ramifications of these hotly demanded medications.

Listen on

Apple Podcasts Spotify

Presented by

Raphael J. Lewis

Raphael J. Lewis

Head of specialist research

Jack

Jack Encarnacao

Research analyst, investigative, Specialist Research team

Explore topics